文献速递泌尿生殖腹部MR

新辅助化疗后膀胱癌nacVI-RADS诊断准确性及阅片者间一致性:一项前瞻性验证研究

Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study.
PubMed 文献 · Eur Radiol · 2024-12-31

前瞻性纳入55例非转移性肌层浸润性膀胱癌患者,在根治性膀胱切除术前接受新辅助化疗,于治疗前后行MRI,由两名有经验放射科医师采用nacVI-RADS评分评估反应,以组织病理为参考标准。nacVI-RADS检测完全反应的敏感度为76.5-85.3%、特异度为76.2-81%,经验更丰富阅片者检测任何残留组织的AUC为0.93(95%CI:0.86-0.99),阅片者间一致性K=0.85。

要点

  • nacVI-RADS检测新辅助化疗完全反应的敏感度为76.5-85.3%、特异度为76.2-81%。
  • 经验更丰富阅片者检测任何残留组织的AUC为0.93(95%CI:0.86-0.99)。
  • 阅片者间一致性最优,K=0.85。

核心结论

  • nacVI-RADS评分系统为评估MIBC患者对全身治疗的反应提供了一种可靠且可重复、结构良好且易于解释的方法。

研究设计与样本

  • 前瞻性研究,纳入55例非转移性MIBC患者(46例男性,84%;9例女性,16%;中位年龄69岁,IQR 66-72岁),在新辅助化疗前和根治性膀胱切除术前行MRI,由两名有经验放射科医师采用nacVI-RADS评分系统评估放射学反应,参考标准为组织病理学发现。

诊断标准与关键数值

  • nacVI-RADS检测新辅助化疗完全反应的敏感度为76.5-85.3%、特异度为76.2-81%;经验更丰富阅片者检测任何残留组织的AUC为0.93(95%CI:0.86-0.99);阅片者间一致性K=0.85;多变量logistic回归中,与反应预测独立相关的变量为nacVI-RADS评分(经验更丰富阅片者p=0.01)和肿瘤消退分级(TRG;p<0.001)。

临床应用与阅片要点

  • 作者认为,nacVI-RADS评分是新辅助全身治疗反应的有效预测指标,可影响治疗决策并改善患者整体管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The primary aim was to determine the performance of neoadjuvant chemotherapy VI-RADS (nacVI-RADS) in predicting response to systemic therapy in patients with MIBC and to evaluate its inter-reader agreement.

MATERIALS AND METHODS: Prospective study, including patients with non-metastatic muscle-invasive bladder cancer (MIBC) who underwent neoadjuvant chemotherapy before radical cystectomy (RC). Patients underwent pre- and post-treatment MRI. Radiological response was evaluated by two experienced radiologists using nacVI-RADS scoring system. Reference standard was defined using histopathological findings. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy were calculated to assess nacVI-RADS performance for each reader. Inter-reader agreement was determined with Cohen's k statistics.

RESULTS: Fifty-five patients with non-metastatic MIBC, 46 males (84%) and 9 females (16%) with a median age of 69 (interquartile range (IQR) 66-72 years) were enrolled. Diagnostic performance of nacVI-RADS in detecting complete response to neoadjuvant chemotherapy showed a sensitivity of 76.5-85.3% and specificity of 76.2-81%. The area under the curve was 0.93 (95% CI: 0.86-0.99) for detecting any residual tissue, for the more experienced reader. Inter-reader agreement was optimal with a K of 0.85. In the multivariable logistic regression model, the variables showing independent correlation with response prediction to neoadjuvant therapy were nacVI-RADS score (p = 0.01 for the more experienced reader) and tumor regression grade (TRG; p < 0.001).

CONCLUSION: NacVI-RADS scoring system offers a reliable and reproducible approach, employing a well-structured and easily interpretable method, to assess the response to systemic therapy in patients with MIBC.

KEY POINTS: Question There is a lack of a standardized approach to distinguish between responders and non-responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Findings The neoadjuvant chemotherapy VI-RADS (nacVI-RADS) score diagnostic performance for detecting complete response to neoadjuvant chemotherapy showed 85.3% sensitivity, 81% specificity, and an AUC of 0.93. Clinical relevance NacVI-RADS score represents a valid predictor of response to neoadjuvant systemic therapy, impacting therapeutic decision-making and improving overall patients' management.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Dehghanpour A, Pecoraro M, Messina E, et al. Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study. Eur Radiol. 2024. PMID: 39738561. doi:10.1007/s00330-024-11327-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。